[Promotion of Personalized Medicine by Appropriate Utilization of Tumor Markers and Companion Diagnostics].

Abstract

Standardization based on clinical guidelines and personalization by molecular-targeted therapy have been introduced into the field of cancer treatment. To select patients appropriate for molecular-targeted drugs, various companion diagnostics have been developed. To catch up with revision of the clinical guidelines and progress of companion diagnostics, the effective utilization of "Guidelines for clinical examinations JSLM2015" is desirable. [Review].